Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPD | P32754 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.45 |
| ▸ | PRKDC | P78527 | 8/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 5/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5836181 | 0.81 | HPD (0.53) | HPDSMN1; SMN2PIK3CAPRKDCHSD11B1 | |
| SCHEMBL5836237 | 0.79 | ALDH1A1 (0.64) | ALDH1A1TSHRDRD2 | |
| SCHEMBL14008573 | 0.78 | HPD (0.46) | HPDSMN1; SMN2PIK3CAPRKDCHSD11B1 | |
| SCHEMBL5836096 | 0.77 | HPD (0.52) | HPDSMN1; SMN2PIK3CAPRKDCHSD11B1 | |
| SCHEMBL6208794 | 0.77 | HPD (0.56) | HPDSMN1; SMN2PIK3CAPRKDCHSD11B1 | |
| SCHEMBL6054648 | 0.77 | HPD (0.46) | HPDSMN1; SMN2PIK3CAALDH1A1TSHR | |
| SCHEMBL3605904 | 0.74 | HTR1A (0.46) | SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL4446744 | 0.74 | DRD2 (0.43) | HPDSMN1; SMN2PIK3CAHSD11B1DRD2 | |
| Trifluoroacetic Acid SCHEMBL4446739 | 0.72 | HPD (0.41) | HPDPIK3CAHSD11B1DRD2SLC6A4 | |
| SCHEMBL5838065 | 0.72 | HPD (0.41) | HPDPIK3CAPRKDCHSD11B1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7056918-B2 | Benzimidazole anti-inflammatory compounds | PFIZER, INC. (US) | 2006-06-06 | — | — | US | disclosed |
| EP-1370557-B1 | BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS | PFIZER PROD INC (US) | 2005-11-16 | — | — | EP | disclosed |
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | PFIZER INC. | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092749-A1 | Novel benzimidazole anti-inflammatory compounds | MAPK1, JAK1, CNKSR1 | HPD 4598/4885SMN1; SMN2 1612/4885PIK3CA 1672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.